Scalper1 News
Puma Biotechnology (PBYI) stock tumbled Thursday after the company released disappointing data late Wednesday, ahead of the annual American Society for Clinical Oncology meeting. The ASCO abstract release also featured positive but somewhat conflicting news on new immuno-oncology drugs from Roche (RHHBY), AstraZeneca (AZN) and Merck (MRK). Puma issued results of its late-stage trial of breast-cancer drug neratinib, whose earlier results were so Scalper1 News
Scalper1 News